ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)
Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.
Article in Journal of immunotherapy (Hagerstown, Md. : 1997). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- Critical considerations in the administration of antineoplastic therapy for patients with malignant solid tumors undergoing hemodialysis.Frontiers in oncology · 2026Review
- Utilizing plasma exchange for severe cytokine release syndrome after CAR-T cell therapy: clinical experience and literature insights.Frontiers in immunology · 2025Review
- Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome.Pharmaceutical research · 2024Review
- Treatment of cytokine release syndrome-induced vascular endothelial injury using mesenchymal stem cells.Molecular and cellular biochemistry · 2024Review
- INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.Transplantation and cellular therapy · 2024Review
- Impact of environment on transmission of antibiotic-resistant superbugs in humans and strategies to lower dissemination of antibiotic resistance.Folia microbiologica · 2023Review
- The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.Frontiers in immunology · 2023Review
- [Three cases of hemodiafiltration for the treatment of CAR-T related grade 3 - 4 cytokine release syndrome after ineffective treatment with IL-6 receptor inhibitors].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil.Frontiers in immunology · 2022Review
- The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions.Frontiers in pharmacology · 2022Review
- Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.Journal of experimental & clinical cancer research : CR · 2021Review
- Reactions Related to CAR-T Cell Therapy.Frontiers in immunology · 2021Review
- Futuristic Non-antibiotic Therapies to Combat Antibiotic Resistance: A Review.Frontiers in microbiology · 2021Review
- Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward.Frontiers in immunology · 2021Review
- Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report.Oncology letters · 2020Article
- Point mutation inJournal for immunotherapy of cancer · 2020Article
- Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors-a narrative review.Annals of translational medicine · 2020Review
- The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma.Signal transduction and targeted therapy · 2020Review
- Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.Expert opinion on biological therapy · 2020Review
- Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?Journal for immunotherapy of cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokine release syndrome (CRS) remains to be a major adverse effect of chimeric antigen receptor T (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma. It was urgent to explore novel strategy for managing severe CRS. We conducted a clinical trial to assess the safety and efficacy of CD19-targeting CAR-T-cells in the treatment of relapsed and chemotherapy-refractory B-ALL and lymphoma. A 10-year-old boy with B-ALL who never achieved minimal residual disease (MRD) negative status after 5 courses of chemotherapy was enrolled into our study and received a total of 3.19×10/kg autologous CD19 CAR-T-cells. Before CAR-T-cell infusion, naive lymphocytes made up 41.8% of bone marrow cells, which were reduced to 1% at the 14th day after transfusion, with MRD<10. However, this patient developed grade 4 CRS, multiple organ failure, hemophagocytic syndrome, neurotoxicity, and severe pulmonary infection after CAR-T-cell therapy. Tocilizumab and glucocorticoids treatment were ineffective for controlling the adverse effects and in contrast, hemofiltration immediately ameliorated the severe CRS and prevented the exacerbation of multiple organ dysfunction, pneumonia, and hydrosarca caused by CAR-T-cell therapy. All side effects disappeared within days following hemofiltration. Hemofiltration helped quickly clear cytokines, speeded up patient recover, and successfully resolved the severe CRS crisis. This was the first report, reporting the successful use of hemofiltration to eliminate adverse reactions of CAR-T-cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.